Your SlideShare is downloading. ×
Rectal cancer   pipeline review, q3 2011
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×

Introducing the official SlideShare app

Stunning, full-screen experience for iPhone and Android

Text the download link to your phone

Standard text messaging rates apply

Rectal cancer pipeline review, q3 2011

152
views

Published on

This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

This report provides information on the therapeutic development for Rectal Cancer, complete with latest updates, and special features on late-stage and discontinued projects.

Published in: Business, Health & Medicine

0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
152
On Slideshare
0
From Embeds
0
Number of Embeds
0
Actions
Shares
0
Downloads
1
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. Rectal Cancer - Pipeline Review, Q3 2011Report SummaryGlobal Markets Direct’s, Rectal Cancer - Pipeline Review, Q3 2011, provides anoverview of the Rectal Cancer therapeutic pipeline. This report provides informationon the therapeutic development for Rectal Cancer, complete with latest updates,and special features on late-stage and discontinued projects. It also reviews keyplayers involved in the therapeutic development for Rectal Cancer. Rectal Cancer -Pipeline Review, Q3 2011 is built using data and information sourced from GlobalMarkets Direct’s proprietary databases, Company/University websites, SEC filings,investor presentations and featured press releases from company/university sitesand industry-specific third party sources, put together by Global Markets Direct’steam.Note*: Certain sections in the report may be removed or altered based on theavailability and relevance of data for the indicated disease.Scope* A snapshot of the global therapeutic scenario for Rectal Cancer.* A review of the Rectal Cancer products under development by companies anduniversities/research institutes based on information derived from company andindustry-specific sources.* Coverage of products based on various stages of development ranging fromdiscovery till registration stages.* A feature on pipeline projects on the basis of monotherapy and combinedtherapeutics.* Coverage of the Rectal Cancer pipeline on the basis of therapeutic class, route ofadministration and molecule type.* Profiles of late-stage pipeline products featuring sections on product description,mechanism of action and research & development progress.* Key discontinued pipeline projects.* Latest news and deals relating to the products.Browse All Pharmaceuticals Market Research ReportsReasons to buy* Identify and understand important and diverse types of therapeutics underdevelopment for Rectal Cancer.* Identify emerging players with potentially strong product portfolio and designeffective counter-strategies to gain competitive advantage.* Plan mergers and acquisitions effectively by identifying players with the mostpromising pipeline.
  • 2. * Devise corrective measures for pipeline projects by understanding Rectal Cancerpipeline depth and focus of Rectal Cancer therapeutics.* Develop and design in-licensing and out-licensing strategies by identifyingprospective partners with the most attractive projects to enhance and expandbusiness potential and scope.* Modify the therapeutic portfolio by identifying discontinued projects andunderstanding the factors that drove them from pipeline.Table of ContentsTable of Contents 2List of Tables 3List of Figures 4Introduction 5Rectal Cancer Overview 6Therapeutics Development 7Rectal Cancer Therapeutics under Development by Companies 9Rectal Cancer Therapeutics under Investigation by Universities/Institutes 11Late Stage Products 17Mid Clinical Stage Products 18Early Clinical Stage Products 19Pre-Clinical Stage Products 20Rectal Cancer Therapeutics - Products under Development by Companies 21Rectal Cancer Therapeutics - Products under Investigation by Universities/Institutes22Companies Involved in Rectal Cancer Therapeutics Development 28Rectal Cancer - Therapeutics Assessment 32Late Stage Drug Profiles 38Rectal Cancer Therapeutics – Drug Profile Updates 193Rectal Cancer Therapeutics - Discontinued Products 195Appendix 196Methodology 196Contact Us 197Disclaimer 197List of TablesNumber of Products Under Development for Rectal Cancer, Q3 2011 16Products under Development for Rectal Cancer – Comparative Analysis, Q3 2011 17Number of Products under Development by Companies, Q3 2011 19Number of Products under Investigation by Universities/Institutes, Q3 2011 21Number of Products under Investigation by Universities/Institutes, Q3 2011 22Number of Products under Investigation by Universities/Institutes, Q3 2011 23Number of Products under Investigation by Universities/Institutes, Q3 2011 24
  • 3. Number of Products under Investigation by Universities/Institutes, Q3 2011 25Comparative Analysis by Late Stage Development, Q3 2011 26Comparative Analysis by Mid Clinical Stage Development, Q3 2011 27Comparative Analysis by Early Clinical Stage Development, Q3 2011 28Comparative Analysis by Pre-Clinical Stage Development, Q3 2011 29Products under Development by Companies, Q3 2011 30Products under Investigation by Universities/Institutes, Q3 2011 31Products under Investigation by Universities/Institutes, Q3 2011 32Products under Investigation by Universities/Institutes, Q3 2011 33Products under Investigation by Universities/Institutes, Q3 2011 34Products under Investigation by Universities/Institutes, Q3 2011 35Products under Investigation by Universities/Institutes, Q3 2011 36Sanofi-Aventis, 2011 37Eli Lilly and Company, 2011 37GenVec, Inc., 2011 38Merck & Co., Inc., 2011 38Celltrion, Inc., 2011 39ImClone Systems Incorporated, 2011 39Oncolytics Biotech Inc., 2011 40Globeimmune, Inc., 2011 40Assessment by Monotherapy Products, Q3 2011 41Assessment by Combination Products 42Assessment by Stage and Route of Administration, Q3 2011 44Assessment by Molecule Type, Q3 2011 46Rectal Cancer Therapeutics – Drug Profile Updates 202Discontinued Products 204List of FiguresNumber of Products under Development for Rectal Cancer, Q3 2011 16Products under Development for Rectal Cancer – Comparative Analysis, Q3 2011 17Products under Development by Companies, Q3 2011 18Products under Investigation by Universities/Institutes, Q3 2011 20Late Stage Products, Q3 2011 26Mid Clinical Stage Products, Q3 2011 27Early Clinical Stage Products, Q3 2011 28Pre-Clinical Stage Products, Q3 2011 29Assessment by Monotherapy Products, Q3 2011 41Assessment by Combination Products, Q3 2011 42Assessment by Route of Administration, Q3 2011 43Assessment by Stage and Route of Administration, Q3 2011 44Assessment by Molecule Type, Q3 2011 45Assessment by Stage and Molecule Type, Q3 2011 46
  • 4. About Us:ReportsnReports is an online library of over 100,000+ market research reports andin-depth market research studies & analysis of over 5000 micro markets. Weprovide 24/7 online and offline support to our customers. Get in touch with us foryour needs of market research reports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page:http://www.facebook.com/pages/ReportsnReports/191441427571689Contact:Mr.Priyank7557 Rambler road,Suite727,Dallas,TX75231Tel: + 1 888 391 5441E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit our Market Research Blog